Background: Previous reports highlighted the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies (mAbs) against coronavirus disease 2019.
Methods: We conducted a prospective study on the clinical outcome and antiviral effects of mAbs added to standard of care therapy in SARS-CoV-2-infected patients with primary antibody defects.
Results: Median time of SARS-CoV-2 quantitative polymerase chain reaction (qPCR) positivity was shorter in 8 patients treated with mAbs (22 days) than in 10 patients treated with standard of care therapy only (37 days, P=.026). Median time of SARS-CoV-2 qPCR positivity from mAb administration was 10 days.
Conclusions: The SARS-CoV-2 mAbs treatment was effective and well tolerated in patients with primary antibody defects.
Keywords: COVID-19; SARS-CoV-2; common variable immunodeficiency; monoclonal antibodies; primary antibody deficiencies.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.